SG11201910127XA - Chimeric antigen receptor against human cd19 antigen and its application - Google Patents

Chimeric antigen receptor against human cd19 antigen and its application

Info

Publication number
SG11201910127XA
SG11201910127XA SG11201910127XA SG11201910127XA SG 11201910127X A SG11201910127X A SG 11201910127XA SG 11201910127X A SG11201910127X A SG 11201910127XA SG 11201910127X A SG11201910127X A SG 11201910127XA
Authority
SG
Singapore
Prior art keywords
antigen
against human
application
antigen receptor
chimeric antigen
Prior art date
Application number
Inventor
Wei Zhang
Original Assignee
Chongqing Prec Biotech Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201710301492.1A external-priority patent/CN107312091B/en
Priority claimed from CN201710613317.6A external-priority patent/CN107226867B/en
Application filed by Chongqing Prec Biotech Company Limited filed Critical Chongqing Prec Biotech Company Limited
Publication of SG11201910127XA publication Critical patent/SG11201910127XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

CHIMERIC ANTIGEN RECEPTOR AGAINST HUMAN CD19 ANTIGEN AND ITS APPLICATION Provided is a chimeric antigen receptor (CAR) against human CD19 antigen, consisting of a single-chain antibody (scFv) recognizing human CD19 antigen, a hinge region, a transmembrane region, and an intracellular signaling domain connected in sequence. The single-chain antibody (scFv) recognizing human CD19 antigen has an amino acid sequence as shown in SEQ ID NOs. 1, 2, 3, 4, 35, 36, or 37. The CAR is expressed in an immune cell, can eliminate a tumor cell, and can be used in a targeted therapy for a tumor. Figure 14
SG11201910127X 2017-05-02 2018-03-08 Chimeric antigen receptor against human cd19 antigen and its application SG11201910127XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710301492.1A CN107312091B (en) 2017-05-02 2017-05-02 Target the Humanized monoclonal antibodies of people CD19 antigen
CN201710613317.6A CN107226867B (en) 2017-07-25 2017-07-25 The Chimeric antigen receptor of anti human CD 19 antigen and its application
PCT/CN2018/078450 WO2018201794A1 (en) 2017-05-02 2018-03-08 Chimeric antigen receptor against human cd19 antigen and application thereof

Publications (1)

Publication Number Publication Date
SG11201910127XA true SG11201910127XA (en) 2019-11-28

Family

ID=64016478

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201910127X SG11201910127XA (en) 2017-05-02 2018-03-08 Chimeric antigen receptor against human cd19 antigen and its application

Country Status (3)

Country Link
DE (1) DE112018002302B4 (en)
SG (1) SG11201910127XA (en)
WO (1) WO2018201794A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202242117A (en) 2020-12-30 2022-11-01 美商亞勞諾斯醫療公司 Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001297703B2 (en) * 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
DK3214091T3 (en) * 2010-12-09 2019-01-07 Univ Pennsylvania USE OF CHEMICAL ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF CANCER
CN105384820A (en) * 2014-08-26 2016-03-09 中国人民解放军总医院 Chimeric antigen receptor and gene and recombinant expression vector thereof, engineered CD19 targeting NKT cell and application thereof
CN104788573B (en) * 2015-05-08 2018-10-16 中国医学科学院血液病医院（血液学研究所） Chimeric antigen receptor hCD19scFv-CD8 α-CD28-CD3 ζ and application thereof
CN104910279B (en) * 2015-06-05 2019-02-22 重庆精准生物技术有限公司 Target Chimeric antigen receptor, the Lentiviral and its preparation method and application of carcinomebryonic antigen
CN107226867B (en) * 2017-07-25 2018-02-06 重庆精准生物技术有限公司 The Chimeric antigen receptor of anti human CD 19 antigen and its application
CN107312091B (en) * 2017-05-02 2019-10-22 重庆精准生物技术有限公司 Target the Humanized monoclonal antibodies of people CD19 antigen

Also Published As

Publication number Publication date
DE112018002302B4 (en) 2020-10-22
WO2018201794A1 (en) 2018-11-08
DE112018002302T5 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
PH12020551160A1 (en) Chimeric antigen receptors targeting cd70
MX2020009774A (en) Antibodies against signal-regulatory protein alpha and methods of use.
MX2021006239A (en) Chimeric antigen receptors targeting cd-19.
PH12020551671A1 (en) Chimeric receptors to dll3 and methods of use thereof
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
EA201992469A1 (en) ANTIGEN SPECIFIC IMMUNE EFFECTIVE CELLS
EP3593812A3 (en) Treatment of cancer using chimeric antigen receptor
NZ741067A (en) Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
MX2020003046A (en) Anti-hla-a2 antibodies and methods of using the same.
WO2016014565A3 (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor
MY192822A (en) An anti-ctla4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition and use
MX2021007006A (en) Humanised anti kallikrein-2 antibody.
PE20181054A1 (en) HUMANIZED ANTI-CD19 ANTIBODIES AND METHODS OF USE
WO2015172339A8 (en) Nucleic acid for coding chimeric antigen receptor protein and t lymphocyte for expression of chimeric antigen receptor protein
AU2015255979B2 (en) Using B-cell-targeting antigen IgG fusion as tolerogenic protein therapy for treating adverse immune responses
MX2017005987A (en) ANTI-IL-1beta ANTIBODIES AND METHODS OF USE.
MX2017005642A (en) Anti-ang2 antibodies and methods of use.
MX2021012336A (en) Humanized anti-dll3 chimeric antigen receptors and uses thereof.
MX2021001592A (en) New car constructs comprising tnfr2 domains.
WO2019112347A3 (en) Antibody or antigen binding fragment thereof for specifically recognizing b cell malignancy, chimeric antigen receptor comprising same, and use thereof
AU2018338423A1 (en) Novel anti-HLA-A2 antibodies and uses thereof
WO2019005639A3 (en) Multi-specific antibodies and methods of making and using thereof
MX2021012692A (en) Anti-mertk antibodies and their methods of use.
WO2018111670A3 (en) Antibodies to human alpha-synuclein